Medicine and Health Sciences Commons^™

Targeting Cell Cycle And Hormone Receptor Pathways In Cancer., C E S Comstock, M A Augello, J F Goodwin, R De Leeuw, M J Schiewer, W F Ostrander, R A Burkhart, A K Mcclendon, Peter Mccue, Edouard J. Trabulsi, Costas D. Lallas, Leonard G Gomella, Md, M M Centenera, Jonathan Brody, Md, L M Butler, W D Tilley, K E Knudsen, Phd

Department of Cancer Biology Faculty Papers

The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G1-arrest. Accordingly, key regulators of the G1-S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability …

Oncolog, Volume 58, Number 06, June 2013, Joe Munch, Amelia Scholtz, Luanne Jorewicz

OncoLog MD Anderson's Report to Physicians (All issues)

• Addressing Emerging Survivorship Issues in Glioblastoma Patients: An increasing number of glioblastoma patients are becoming '' long-term'' survivors-living 3 or more years after diagnosis
• Prediction Tool Helps Determine Whether Older Breast Cancer Patients will benefit from Radiation: A statistical tool is now available to predict the likely individual benefit of radiation therapy for older women who have undergone breast-conserving surgery for breast cancer
• Sequential Multidrug Regiman May Offer an Alternative to Standard Cisplatin-Based Therapy for Urothelial Cancer: Cisplatin-based chemotherapy is the standard neoadjuvant treatment for high-risk, surgically resectable, invasive urothelial cancer. But some patients are not good candidates for this …

Oncolog, Volume 58, Number 03, March 2013, Sarah Bronson, Zach Bohannan, Bryan Tutt

OncoLog MD Anderson's Report to Physicians (All issues)

• Advances in Pulmonary Medicine Facilitate Cancer Diagnosis, Treatment: The lungs present unique challenges in cancer diagnosis and treatment-navigating a maze of bronchi to find and sample tissue that will lead to an accurate diagnosis of lung cancer, for example, or deciding whether to proceed with treatment for cancer in the presence of concomitant lung disease
• New Drugs Increase Treatment Options for Patients with Imatinib-Resistant Chronic Myeloid Leukemia: In the past year, several new targeted drugs have been approved as second-line treatments for imatinib-resistant chronic myeloid leukemia (CML). These drugs include the second-generation tyrosine kinase inhibitor bosutinib and the third-generation tyrosine …

Gleevec, An Abl Family Inhibitor, Produces A Profound Change In Cell Shape And Migration, Zaozao Chen, Elizabeth Lessey, Matthew E. Berginski, Li Cao, Jonathan Li, Xavier Trepat, Michelle Itano, Shawn M. Gomez, Maryna Kapustina, Cai Huang, Keith Burridge, George Truskey, Ken Jacobson

Markey Cancer Center Faculty Publications

The issue of how contractility and adhesion are related to cell shape and migration pattern remains largely unresolved. In this paper we report that Gleevec (Imatinib), an Abl family kinase inhibitor, produces a profound change in the shape and migration of rat bladder tumor cells (NBTII) plated on collagen-coated substrates. Cells treated with Gleevec adopt a highly spread D-shape and migrate more rapidly with greater persistence. Accompanying this more spread state is an increase in integrin-mediated adhesion coupled with increases in the size and number of discrete adhesions. In addition, both total internal reflection fluorescence microscopy (TIRFM) and interference reflection …

Oncolog, Volume 58, Number 01, January 2013, Joe Munch, Sunni Hosemann

OncoLog MD Anderson's Report to Physicians (All issues)

• Emerging Vaccines Take Aim at Preventing Recurrent Breast Cancer: Myriad advances have been made in the treatment of breast cancer, and cures are achieved in many patients. However, there are still patients whose cancer recurs, and most of these patients will die of their disease. This indicates a need for other therapies that can be used to prevent recurrent disease. One potential option is breast cancer vaccines.
• Compass: Hepatocellular Carcinoma: Concomitant liver disease affects treatment options
• HOUSE CALL: Music Therapy-Music therapists help cancer patients manage stress and side effects

A Phase 1b Study Of Humanized Ks-Interleukin-2 (Huks-Il2) Immunocytokine With Cyclophosphamide In Patients With Epcam-Positive Advanced Solid Tumors., Joseph P Connor, Mihaela C Cristea, Nancy L Lewis, Lionel D Lewis, Philip B Komarnitsky, Maria R Mattiacci, Mildred Felder, Sarah Stewart, Josephine Harter, Jean Henslee-Downey, Daniel Kramer, Roland Neugebauer, Roger Stupp

Kimmel Cancer Center Faculty Papers

BACKGROUND: Humanized KS-interleukin-2 (huKS-IL2), an immunocytokine with specificity for epithelial cell adhesion molecule (EpCAM), has demonstrated favorable tolerability and immunologic activity as a single agent.

METHODS: Phase 1b study in patients with EpCAM-positive advanced solid tumors to determine the maximum tolerated dose (MTD) and safety profile of huKS-IL2 in combination with low-dose cyclophosphamide. Treatment consisted of cyclophosphamide (300 mg/m2 on day 1), and escalating doses of huKS-IL2 (0.5-4.0 mg/m2 IV continuous infusion over 4 hours) on days 2, 3, and 4 of each 21-day cycle. Safety, pharmacokinetic profile, immunogenicity, anti-tumor and biologic activity were evaluated.

RESULTS: Twenty-seven patients were treated …